The abstract is read at the publisher; the summary is JClub's.
Elevated TARBP2 expression in renal cell carcinoma is linked to poor prognosis and immune checkpoint blockade resistance, and it promotes immune escape by upregulating B7-H3.
- Why it matters: RCC often resists immune checkpoint blockade, but the molecular drivers of immune evasion in its tumor microenvironment are not fully defined.
- What they did: The study identified TARBP2 as a regulator of B7-H3, tested TARBP2 function in RCC cells for effects on T-cell and NK-cell accumulation and cytotoxicity, and mapped a mechanism via nuclear TARBP2–53BP1 interaction that inhibits 53BP1 phase separation and p53 activation.
- The result: TARBP2 inhibition increased intratumoral immune activity and significantly enhanced ICB efficacy when combined with adoptive NK cell therapy, supporting TARBP2 as a therapeutic target to overcome resistance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.